Table 4.
Number of hemophilia patients from WAPPS‐Hemo switching between FVIII concentrates
| FVIII products | Switch to | Total | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Plasma‐derived | Plasma‐derived with vWF | First‐gen rec. full‐length | Second‐gen rec. full‐length | Third‐gen rec. full‐length | Second‐gen rec. BDD | Third‐gen rec. BDD | Fourth‐gen rec. BDD | Third‐gen EHL rec. BDD‐PEGylated | Fourth‐gen EHL rec. Fc‐Fusion | Third‐gen EHL rec. single‐chain | |||
| Switch from | Plasma‐derived | 2 | 8 | 6 | 9 | 2 | 3 | 1 | 0 | 0 | 6 | 0 | 37 |
| Plasma‐derived with vWF | 4 | 26 | 6 | 20 | 5 | 2 | 0 | 0 | 2 | 10 | 1 | 76 | |
| First‐gen rec. full‐length | 4 | 11 | 0 | 15 | 18 | 7 | 6 | 1 | 0 | 2 | 0 | 64 | |
| Second‐gen rec. full‐length | 5 | 16 | 16 | 24 | 57 | 6 | 2 | 4 | 2 | 56 | 3 | 191 | |
| Third‐gen rec. full‐length | 0 | 0 | 8 | 5 | 6 | 3 | 13 | 4 | 12 | 50 | 1 | 102 | |
| Second‐gen rec. BDD | 1 | 2 | 5 | 7 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 17 | |
| Third‐gen rec. BDD | 0 | 0 | 0 | 0 | 2 | 1 | 5 | 2 | 2 | 19 | 1 | 32 | |
| Fourth‐gen rec. BDD | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 5 | |
| Third‐gen EHL rec. BDD‐PEGyl | 0 | 0 | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | |
| Fourth‐gen EHL rec. Fc‐Fusion | 0 | 1 | 0 | 4 | 9 | 0 | 6 | 6 | 30 | 0 | 0 | 56 | |
| Third‐gen EHL rec. single‐chain | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 5 | 0 | 7 | |
| Total | 16 | 65 | 41 | 86 | 102 | 22 | 34 | 17 | 49 | 153 | 6 | 591 | |
BDD, B‐domain deleted; EHL, extended half‐life; FVIII, factor VIII; rec, recombinant;vWF, von Willebrand factor; WAPPS, Web‐Accessible Population Pharmacokinetics Service.